Clinical Study

A Randomized Controlled Trial Evaluating the Effects of Diosmin in the Treatment of Radicular Pain

Yinhe Wang,1 Xin Fang,2 Lei Ye,3 Yishan Li,4 Hongfei Shi,1 and Yang Cao2,5

1Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu 210008, China
2Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden
3Department of Pharmacology, Qianfo Hill Institute of Shandong Province, Jinan, Shandong 250004, China
4Department of International Training, PLA University of Science and Technology, Nanjing, Jiangsu 210007, China
5Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, 70182 Örebro, Sweden

Correspondence should be addressed to Yinhe Wang: milkyway199@hotmail.com and Xin Fang: xin.fang@ki.se

Received 9 June 2017; Revised 15 August 2017; Accepted 6 September 2017; Published 8 October 2017

Academic Editor: Adair Santos

Copyright © 2017 Yinhe Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diosmin has been widely used to treat patients with vascular pain for its potent anti-inflammatory and analgesic effects. To evaluate the therapeutic effects of Diosmin in the treatment of radicular pain, we conducted an investigator-initiated, randomized, active-controlled noninferiority trial between January 1, 2009, and December 1, 2010. Diosmin (50 mg/kg/day) was orally administered to treat the radicular pain in 150 patients for one month. Another 150 patients with the same symptom were given 20% 250 ml mannitol (1 g/kg/day) for 7 days and dexamethasone (10 mg/day) for 3 days intravenously. Short-term relief and long-term relief were measured. Secondary outcomes include improvement in functional and psychological status, return to work, and reduction in anti-inflammatory analgesic drugs intake. Patients treated with oral Diosmin achieved reduction in radicular pain. The total satisfaction rate of Diosmin group was 84.7% [95% confidence interval (CI): 77.9%, 90.0%], and the complete satisfaction rate was 50.7% (95% CI: 42.4%, 58.9%). No statistically significant difference was found between the Diosmin group and the active-control group regarding patient satisfaction. No adverse effects were found during the study period. Our study suggests that clinical application of Diosmin with a dose of 50 mg/kg/day might reduce the radicular pain. This trial is registered with ISRCTN97157037.

1. Introduction

Radicular pain is a common chronic pain, which is commonly caused by disc herniation, although a space occupying lesion in the lumbosacral spine or spondylolisthesis can also result in such clinical condition. The main cause of lumbosacral radiculopathy is intervertebral disc herniation. Among patients with lumbosacral radiculopathy, about 10–15% had surgery eventually, but overall the majority recovers with conservative management. In general, nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are commonly used to treat inflammatory pain in clinical practices [1].

Studies suggest that the mechanism of radicular pain is due to the inflammatory nerve roots [2]. Chemical radiculitis, a chemically mediated noncellular inflammatory reaction, which may occur through a disc rupture and imply irritation of the nerve root by perineural spread of nucleus pulposus, might be a complementary explanation. Nucleus pulposus is inflammatogenic and leukotactic [3]. Previous study shows that inflammatory processes participate in nerve pain to secrete proinflammatory cytokines like 5-HT and TNF and suppress anti-inflammatory factors such as interleukin-10 [4]. Mechanical compression and hypoxia, directly or indirectly caused by disc herniation, blood supply, and cerebrospinal fluid flow of spinal nerve roots and peripheral nerves are related to abnormal sensations and pain, shown as possible causes of symptoms [5].

Drug therapy, physical therapy, and psychotherapy, surgery, bed rest, acupuncture, spinal cord stimulation,
cryotherapy, and radiofrequency thermocoagulation have been used for treating radicular pain [6]. For more than 50% of patients with the symptom, physicians suggest using simple analgesics and resuming daily activities. Although there is only limited evidence of the long-term effectiveness, opioids analgesic has also been used to treat radicular pain. However, some negative outcomes, for example, higher risk for developing problematic opioid use or addiction during long-term opioid therapy, have been observed in patients with mental and substance use disorders [7].

Anti-inflammatory cytokine therapy may be an effective treatment of sciatica which resulted from disc herniation due to its capability of preventing the dorsal root ganglion compartment syndrome, which might be a side effect of applying nucleus pulposus topically. Flavonoids, a group of plant extracts, have been widely used in biochemistry and pharmacology because of their anti-inflammatory, immunomodulatory, and antioxidant effects in vivo and in vitro [8]. Flavonoids may improve lymphatic drainage by significantly increasing lymphatic flow. Their purified micronized compound has been used to treat chronic venous insufficiency and the beneficial effects have implication in treating disc herniation related sciatica.

Although Diosmin has been widely used in treating various pains for patients with intravenous vascular pain, to the best of our knowledge, there is no published data so far for the indication of radicular pain. We compared the degree of pain relief and physical function improvement in the radicular pain patients treated by Diosmin and an active treatment in the presented study.

2. Materials and Methods

2.1. Study Design. This investigator-initiated, randomized, active-controlled, noninferiority trial was carried out in the Department of Orthopedic Surgery, Drum Tower Hospital of Nanjing University Medical School between January 1, 2009, and December 1, 2010. The protocol was approved by the Ethics Committees of Drum Tower Hospital of Nanjing University Medical School. Three hundred consecutive outpatients with radicular pain (previously diagnosed with unilateral leg pain greater than low back pain, positive straight leg raising test, radiating pain in lower limbs, numbness, and paresthesia in the same distribution) [9] and/or evidence of nerve root compromise, lumbar disc degeneration, herniation, or protrusion on magnetic resonance scan were enrolled. Informed signed consent was obtained from all the patients. The trial was registered at the ISRCTN registry (number ISRCTN97157037) “ (http://www isrctn.com/ISRCTN97157037”.

2.2. Inclusion and Exclusion Criteria. The inclusion criteria were preliminarily diagnosis of radicular pain; age ≥ 18 years; pain duration ≥ 30 days; being previously treated with nonsteroidal anti-inflammatory drugs, opioid medications, or physical therapy without pain relief for more than one month; being with normal or slight decrease in the height of disc space on lateral plain X-ray film; and being initially considered eligible for surgical intervention.

Based on patient’s history and clinical and imaging examinations, the exclusion criteria were patients with spondylolisthesis, lumbar canal stenosis, isthmic or degenerative spondylolisthesis, inflammatory arthritis, spinal instability, infection, previous lumbar surgery, neurologic disease, tumor, or psychological disorders (such as depression or using antidepressants or anxiolytic medications). Patients with lumbar intervertebral disc protrusion who were diagnosed according to magnetic resonance by a radiologist and an orthopedic surgeon and needed surgery were also excluded.

2.3. Treatments. Three hundred outpatients with radicular pain were randomly assigned into the Diosmin group and the active-control, that is, mannitol and dexamethasone [10], group with 1:1 ratio using computer-aided random assignment. Diosmin group received Diosmin (Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.) per os, 900 mg, tid for 2 weeks followed by bid for 2 weeks, and lastly 450 mg bid as maintenance dose for at least one month [11, 12]. Control group received 20% mannitol (CR Double-Crane Pharmaceuticals Co., Ltd.) 250 ml (1 g/kg/day) and dexamethasone (Furuitang Pharmaceutical Co., Ltd.) 10 mg/day intravenously guttae for the first 3 days and followed by mannitol for 4 days. In both groups, the courses of treatment lasted at least one month. The patients with serious pain [visual analog scale (VAS) > 8 in our study] were given diclofenac (Novartis) 75 mg/day for maximum 7 days. In case symptoms appeared again one month after last symptoms disappeared, the same regimen was given again.

2.4. Outcomes and Follow-Ups

Short-Term Outcomes. A visual analog scale (VAS) was used to measure the main outcomes [13]. To measure the pain that the patient had ever perceived during a particular time period, a standard 10-centimeter line was used in the VAS in which 0–0.4 cm meant no pain and 7.5–10 cm meant severe pain. A numerical rating scale (NRS) [13], with points ranging from 0 (no pain) to 100 (worst pain experienced in the last 1 week), was used. VAS and NRS outcome measures were collected just after the procedure, weeks 2 and 8 after procedure, respectively. To comply with the conventional scaling, VAS scores were rescaled to 0–100 and NRS scores to 0–10. The Roland-Morris Questionnaire (RM-Q) [14] was filled by the patient thrice, just after procedure and weeks 2 and 8 too.

Long-Term Outcomes. The patients had regular visit to the outpatient department of the hospital or we took regular telephone follow-up for those who did not have regular visit. Current pain level and satisfaction were recorded during each visit or follow-up for every patient. The long-term outcomes were evaluated in the 24th month after randomization by hospital visit or telephone interview. Medication usage and posttreatment satisfaction were examined. Usage of NSAIDs or opioid medications was graded as follows: 1, never; 2, occasional; 3, regular. A three-grade scale was used to rate patient’s satisfaction: 1, completely satisfied (no pain at all time and no restriction of activities); 2, satisfied (slight pain
### Table 1: Baseline characteristics of the patients.

|                          | Diosmin group  | Control group | \(P\) value |
|--------------------------|----------------|---------------|-------------|
|                          | \(n = 150\)    | \(n = 150\)   |             |
| Male (\(n, \%\))         | 76, 50.7%      | 73, 48.7%     | 0.729       |
| Age (years, mean ± SD)   | 41 ± 6.3       | 42 ± 7.4      | 0.215       |
| Treatment course (months, mean ± SD) | 4 ± 1.4 | 4 ± 1.5 | 1.000       |
| Duration of pain (\(n, \%\)) |              |               |             |
| <3 months                | 45, 30.0%      | 47, 31.3%     |             |
| 3–12 months              | 62, 41.3%      | 65, 65%       | 0.909       |
| 13–36 months             | 29, 19.3%      | 27, 18.0%     |             |
| >36 months               | 14, 9.3%       | 11, 7.3%      |             |
| Pretreatment with opioids (\(n, \%\)) |          |               |             |
| None                     | 118, 78.5%     | 114, 76.0%    | 0.849       |
| <60 morphine equivalents/day | 21, 14.0%    | 23, 15.3%     |             |
| ≥60 morphine equivalents/day | 11, 7.3%      | 13, 8.7%      |             |
| Current smoker (\(n, \%\)) | 21, 14.0%       | 23, 15.3%     | 0.744       |
| Obesity (\(n, \%\))     | 23, 15.3%      | 25, 16.7%     | 0.753       |
| Level of lesion (culprit nerve root, \(n, \%\)) |          |               |             |
| L2-3/L3                  | 9, 6.0%        | 11, 7.3%      | 0.788       |
| L3-4/L4                  | 13, 8.7%       | 15, 10.0%     |             |
| L4-5/L5                  | 99, 66.0%      | 101, 67.3%    |             |
| L5-S1/S1                 | 29, 19.3%      | 23, 15.3%     |             |
| Baseline pain scores (mean ± SD) |            |               |             |
| VAS                      | 89 ± 11        | 91 ± 4        | 0.037       |
| RM-Q                     | 17.2 ± 2.7     | 17.4 ± 2.3    | 0.490       |
| NRS                      | 7.8 ± 0.7      | 7.8 ± 0.3     | 0.222       |
| Number of patients with serious pain given diclofenac (\(n, \%\)) | 6, 3.9%        | 5, 3.3%       | 0.759       |

SD, standard deviation; VAS, visual analog scale; RM-Q, Roland-Morris Questionnaire; NRS, numerical rating scale.

that requires no medication and mild restriction of activities; 3, unsatisfied (moderate to severe pain that requires medication and moderate to severe restriction of activities) [15].

**Adverse Effect.** Adverse effects, including gastrointestinal discomfort, were recorded in adverse effects form through patients’ complaint during outpatient department visit or follow-up.

To minimize investigator bias, the independent investigator who recorded all the results was blinded to both therapeutic groups.

### 2.5. Statistical Analysis

Intention-to-treat analysis was used to avoid various misleading artifacts that could arise in the trial such as nonrandom attrition of the patients. Missing values were imputed by the last-observation-carried-forward method as recommended [16]. All results were expressed as mean ± standard deviation (SD) for continuous variables and proportion for categorical variables. Student’s \(t\)-test and \(\chi^2\) test were used for statistical comparisons for continuous variables and categorical variables, respectively. VAS, NRS, and RM-Q scores of pretreatment and posttreatment at different time points were presented as means with corresponding 95% confidence intervals (CIs) and compared using two-way analysis of variance. Two-sided \(P\) values < 0.05 and one-sided \(P\) values < 0.025 were considered statistically significant for baseline comparison and for posttreatment comparison, respectively. Statistical software programmes IBM SPSS 24 (IBM Corporation, Armonk, New York) and Stata 14.2 (StataCorp LLC, College Station, Texas, USA) were used for all the analyses.

### 3. Results

#### 3.1. Characteristics of Patients at Baseline

In total, 300 patients with radicular pain were included in the study and were randomly assigned into the Diosmin group (\(n = 150\)) and the active-control group (\(n = 150\)). The baseline characteristics were balanced between the two groups and no statistically significant difference was found (Table 1). The age of patient is 41 ± 6.5 years and 42 ± 7.4 years (\(t = 1.244, P = 0.215\)) in the Diosmin group and the active-control group, respectively. The courses of treatment are 4 ± 1.4 months and 4 ± 1.5 months (\(t = 0.000, P = 1.000\)) in the Diosmin and the active-control group, respectively. Duration of pain ranged from 1 month to 48 months and there was no statistically
Table 2: Comparisons of mean RM-Q, NRS, and VAS scores (95% CI) between pre- and posttreatment.

| Outcome | Pretreatment | Diosmin 2 weeks | 8 weeks | Control 2 weeks | 8 weeks |
|---------|--------------|----------------|---------|----------------|---------|
| RM-Q    | 17.2 (16.8, 17.6) | 11.8 (11.3, 12.3)* | 9.1 (8.7, 9.5)* | 17.4 (17.0, 17.8) | 11.3 (10.9, 11.7)* |
| NRS     | 7.8 (7.7, 7.9) | 5.7 (5.5, 5.8)* | 3.4 (3.3, 3.5)* | 7.8 (7.7, 7.9) | 5.4 (5.3, 5.4)* |
| VAS     | 89 (87, 91) | 52 (51, 53)* | 36 (34, 38)* | 91 (90, 92) | 55 (53, 57)* |

*One-sided \( P < 0.025 \), within group comparison was performed using two-way analysis of variance. RM-Q, Roland-Morris Questionnaire; NRS, numerical rating scale; VAS, visual analog scale.

Table 3: Patient satisfaction and other medication usage at the 24th month after randomization.

| Satisfaction of patients: \( n, \% (95\% \text{ CI}) \) | Diosmin | Control | \( P \) value |
|-------------------------------------------------|---------|---------|-------------|
| Completely satisfied                             | 76, 50.7% (42.4%, 58.9%) | 77, 51.3% (43.0%, 59.6%) | 0.967 |
| Satisfied                                        | 51, 34.0% (26.5%, 42.2%) | 49, 32.7% (25.2%, 40.8%) | |
| Unsatisfied                                      | 23, 15.3% (10.0%, 22.2%) | 24, 16.0% (10.5%, 22.9%) | |
| Other medication usage: \( n, \% (95\% \text{ CI}) \) | 46, 30.7% (23.4%, 38.7%) | 43, 28.7% (21.6%, 36.6%) | 0.705 |
| Nonsteroidal anti-inflammatory drugs: \( n, \% (95\% \text{ CI}) \) | 41, 27.3% (20.4%, 35.2%) | 39, 27.7% (19.2%, 33.8%) | 0.794 |
| Opioid medications: \( n, \% (95\% \text{ CI}) \) | 33, 22.0% (15.7%, 29.5%) | 36, 24.0% (17.4%, 31.6%) | 0.681 |

Table 4: Frequency of overall medication usage at the 24th month after randomization: \( n, \% (95\% \text{ CI}) \).

| Overall medication usage | Diosmin | Control | \( P \) value |
|--------------------------|---------|---------|-------------|
| None                     | 104, 69.3% (61.3%, 76.6%) | 107, 71.3% (63.4%, 78.4%) | 0.845 |
| Occasional               | 33, 22.0% (15.7%, 29.5%) | 29, 19.3% (13.3%, 26.6%) | |
| Regular                  | 13, 8.7% (4.7%, 14.4%) | 14, 9.3% (5.2%, 15.2%) | |

A significant difference between two groups (\( \chi^2 = 0.546, P = 0.909 \)). The level of lesion and baselines pain score for both groups are shown in Table 1. Statistically significant difference was only found for VAS (\( t = 2.093, P = 0.037 \); Table 1).

3.2. Clinical Outcome. All the patients completed three follow-up visits as planned and there was no drop out during the study period. In both groups, there was statistically significant improvement in the RM-Q, NRS, and VAS scores at week 2 and week 8 of posttreatment compared to pretreatment (Table 2). Improvement in RM-Q, NRS, and VAS scores retained during follow-up and was statistically significant (Table 2).

The difference of patient satisfaction and other medication usage between the two groups at the 24 months after randomization were not statistically significant (Table 3).

Frequency of overall medication usage (narcotics, or opioid medications, or both opioid medications and NSAIDs) after treatment decreased notably in both groups (data not shown). Again, no statistically significant difference was found between the two groups (Table 4).

3.3. Adverse Effects. There was no serious adverse effect in both groups. Five patients in the control group reported mild nausea without vomiting. The symptoms disappeared after drug withdrawal and no special treatment was required.

4. Discussion

A significant proportion of patients suffering from chronic pain with radicular component have a high disability index [17, 18]. Studies have indicated that potential causes of radicular pain include nerve root compression, reduced blood flow, increased endoneurial edema, and fluid pressure in associated nerve roots, which may cause neuronal ischemia and/or sensory disorder [19]. The treatment of radicular pain has traditionally been limited to either conservative management or surgical methods [20]. In general, patients with radicular pain can be treated conservatively. In recent decades, invasive procedures such as lumbar spine surgery have been performed increasingly on patients with radicular pain; however radicular pain was observed after operations [21]. Radicular pain may sometimes become more severe following a steroid epidural block. Side effects after using steroids have been related to the chemistry and pharmacology of the steroids [22]. A recent 1-year follow-up study found a recovery rate of 95% among patients with sciatica randomized to either early surgery or prolonged conservative treatment [23]. Another report found that patients with lumbar intervertebral disc herniation improved substantially after either surgical or conservative treatment [24]. However, compared to the patients treated conservatively, work or disability outcomes at 2 years either with or without work
compensation were not improved for patients treated surgically [24].

Reports showed that conservative treatment for radicular pain had satisfactory results. Besides treating medical and psychiatric comorbidities, conservative treatments include physiotherapy, meditation, transcutaneous electrical nerve stimulation, and relaxation techniques, activity, exercise, and/or stretching to reduce spinal extension [25]. Although oral analgesics (usually NSAIDs and opioids) are prescribed frequently, the effectiveness is limited. Both analgesics might have substantial side effects after long-term usage. Regarding whether the benefit of one class is over another, there is no conclusive evidence. Studies have associated NSAIDs with gastrointestinal bleeding, renal impairment, and potentially elevated cardiovascular risk in the case of cyclooxygenase-2 inhibitors [26]. On the other hand, opioids have been associated with potential abuse and tolerance and dose-related risk of death [27]. Especially in the setting of long-term opioid therapy, some patient characteristics including mental disorders and substance abuse have been identified as risk factors associated with negative outcomes of problematic use or addiction in observational studies [7].

From chemical aspect, experimental studies have shown the spontaneous resorption of disk herniation [28] and the immunogenicity of intervertebral disk [29–32]. Inflammatory mediators including phospholipase A2, prostaglandin E2, interleukin-1α, IL-1β, IL-6, tumor necrosis factor-α, and nitric oxide (NO) have also been identified around and within intervertebral disk tissue. The evidence indicates that inflammatory factors TNF-α as well as NO, prostaglandin E2 (PGE2), and IL-6 are the main candidates among substances potentially responsible for nerve root pain according to the current pathophysiology [33–38]. The proinflammatory substances secreted by nucleus pulposus may also contribute to the damaged nerve roots in the absence of mechanical compression [39].

Our study indicates that patients treated orally with Diosmin achieved reduction in radicular pain, as measured by the NRS, RM-Q, and VAS. The satisfaction rates of the patients were 84.7% (95% CI: 77.9%, 90.0%) and 84.0% (95% CI: 77.1%, 89.5%) after 24 months of randomization for the Diosmin group and the active-control group, respectively. In general, all primary outcomes were similar between the Diosmin group and the control group without statistical significance. No serious adverse effects were found in both groups. However five patients in the control group reported mild nausea and the symptoms get disappeared after drug withdrawal and no special intervention was required.

Improved venous tone and capillary bed microcirculation, reduced capillary permeability, increased lymphatic drainage, and inhibited inflammatory reactions have been identified as main mechanisms of Diosmin’s action [40]. Being potent inhibitors of PGE2 and thromboxane A2, Diosmin and other flavonoids may inhibit leukocyte activation, migration, and adhesion. Diosmin provides protection against microcirculatory damage through decreasing the plasma levels of endothelial adhesion molecules and reducing neutrophil activation significantly [41].

Although our study provided evidence that Diosmin may have similar pain relief effect compared with the active-control treatment mannitol plus dexamethasone, we have to acknowledge that our study was a single center trial and limited by the small number of patients. Further multicenter randomized controlled clinical trial with larger sample size is required to confirm the clinical application of Diosmin in treating radicular pain.

5. Conclusions

As a potential promising therapeutic drug, Diosmin may reduce radicular pain that might partly be attributed to its anti-inflammatory and analgesic components. Its effects are similar to currently used active treatment mannitol plus dexamethasone.

Abbreviations

NSAID: Nonsteroidal anti-inflammatory drug
VAS: Visual analog scale
NRS: Numerical rating scale
RM-Q: Roland-Morris Questionnaire
SD: Standard deviation
IL: Interleukin
TNF: Tumor necrosis factor
NO: Nitric oxide
PGE2: Prostaglandin E2.

Disclosure

The funding sources had no involvement or influence in the preparation of the manuscript.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

Yinhe Wang and Yang Cao conceived and designed the study; Yishan Li, Lei Ye, and Hongfei Shi conducted the clinical trial; Xin Fang performed the statistical analysis and data interpretation. All the authors contributed to manuscript drafting and revised the paper critically for intellectual content and approved the final version.

Acknowledgments

Yinhe Wang’s work was supported by grants from the National Natural Science Foundation of China (nos. 81271997 and 81401793), the Medical Science and Technology Development Foundation, Department of Health of Nanjing City (no. ZKX10007), the Postdoctoral Science Foundation of China (no. 2010048130), and the Medical Key Personnel Program of Jiangsu Province, China (no. RC2011150). The authors thank Li Liu, Anlong Liu, Hongfei Shi, and Yong Qiu who contributed to the clinical trial work.
References

[1] B. L. Kidd and L. A. Urban, “Mechanisms of inflammatory pain,” *British Journal of Anaesthesia*, vol. 87, no. 1, pp. 3–11, 2001.

[2] K. Omaker and R. R. Myers, “Pathogenesis of sciatic pain: role of herniated nucleus pulposus and deformation of spinal nerve root and dorsal root ganglion,” *Pain*, vol. 78, no. 2, pp. 99–105, 1998.

[3] J. Govind, “Lumbar radicular pain,” *Australian Family Physician*, vol. 33, no. 6, pp. 409–412, 2004.

[4] H. Kobayashi, S.-I. Kikuchi, S.-I. Konno, K. Kato, and M. Sekiguchi, “Interaction of 5-hydroxytryptamine and tumor necrosis factor-α to pain-related behavior by nucleus pulposus applied on the nerve root in rats,” *Spine*, vol. 36, no. 3, pp. 210–218, 2011.

[5] O. Sugawara, Y. Atsuta, T. Iwahara, T. Muramoto, M. Watakabe, and Y. Takemitsu, “The effects of mechanical compression and hypoxia on nerve root and dorsal root ganglia: An analysis of ectopic firing using an in vitro model,” *Spine*, vol. 21, no. 18, pp. 2089–2094, 1996.

[6] A. Malmivaara, U. Häkkinen, T. Aro et al., “The treatment of acute low back pain - Bed rest, exercises, or ordinary activity?” *New England Journal of Medicine*, vol. 332, no. 6, pp. 351–355, 1995.

[7] M. J. Edlund, D. Steffick, T. Hudson, K. M. Harris, and M. Sullivan, “Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain,” *Pain*, vol. 129, no. 3, pp. 355–362, 2007.

[8] D. Nolte, S. Pickelmann, M. Möllmann et al., “Effects of the phlebotropic drug Daflon 500 mg on postischemic microvascular disturbances in striated skin muscle: An intravital microscopic study in the hamster,” *Journal of Laboratory and Clinical Medicine*, vol. 134, no. 5, pp. 526–535, 1999.

[9] B. W. Koes, M. W. Van Tulder, and W. C. Peul, “Diagnosis and treatment of sciatica,” *British Medical Journal*, vol. 334, no. 7607, pp. 1313–1317, 2007.

[10] Y. Zheng, J. Wang, C. Yuan et al., “Effect of intravenous manitol or dexamethasone on low back and leg pain after lumbar fusion surgery,” *Chinese Journal of Reparative and Reconstructive Surgery*, vol. 28, no. 5, pp. 544–548, 2014.

[11] Y.-X. Lu and Q.-Y. Ye, “Nursing experience of one case of allergic shock due to Safflower injection,” *Chinese and Foreign Medical Research*, vol. 11, no. 23, p. 122, 2013.

[12] M. Huang, W. Huang, and L. Lin, “Clinical research on the treatment of acute postpartum perineum edema and pain with Diosmin,” *Modern Journal of Integrated Traditional Chinese and Western Medicine*, vol. 18, no. 23, pp. 2792–2794, 2009.

[13] G. A. Hawker, S. Mian, T. Kendzerska, and M. French, “Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and measure of Intermittent and Constant Osteoarthritis Pain (ICOAP),” *Arthritis Care & Research*, vol. 63, supplement 11, pp. S240–S252, 2011.

[14] M. Roland and J. Fairbank, “The Roland-Morris disability questionnaire and the Oswestry disability questionnaire,” *Spine*, vol. 25, no. 24, pp. 315S–324S, 2000.

[15] B. Peng, X. Pang, Y. Wu, C. Zhao, and X. Song, “A randomized placebo-controlled trial of intradiscal methylene blue injection for the treatment of chronic discogenic low back pain,” *Pain*, vol. 149, no. 1, pp. 124–129, 2010.

[16] I. R. White, N. J. Horton, J. Carpenter, and S. J. Pocock, “Strategy for intention to treat analysis in randomised trials with missing outcome data,” *British Medical Journal*, vol. 342, no. 7803, pp. 910–912, 2011.

[17] L. Manchikanti and J. A. Hirsch, “Clinical management of radicular pain,” *Expert Review of Neurotherapeutics*, vol. 15, no. 6, pp. 681–693, 2015.

[18] D. Hoy, L. March, and P. Brooks, “The global burden of low back pain: estimates from the global burden of disease 2010 study,” *Annals of the Rheumatic Diseases*, vol. 73, no. 6, pp. 968–974, 2014.

[19] T. Igarashi, S. Yabuki, S. Kikuchi, and R. R. Myers, “Effect of acute nerve root compression on endoneural fluid pressure and blood flow in rat dorsal root ganglia,” *Journal of Orthopaedic Research*, vol. 23, no. 2, pp. 420–424, 2005.

[20] E. J. Carragee, “Persistent low back pain,” *The New England Journal of Medicine*, vol. 352, no. 18, pp. 1891–1898, 2005.

[21] P. Fritzell, O. Hägg, P. Wessberg, and A. Nordwall, “2001 Volvo award winner in clinical studies: lumbar fusion versus nonsurgical treatment for chronic low back pain: a multicenter randomized controlled trial from the Swedish Lumbar Spine Study Group,” *Spine*, vol. 26, no. 23, pp. 2521–2532, 2001.

[22] S. Abdi, S. Datta, A. M. Tresco et al., “Epidural steroids in the management of chronic spinal pain: a systematic review,” *Pain Physician*, vol. 10, no. 1, pp. 185–212, 2007.

[23] W. C. Peul, H. C. Van Houwelingen, W. B. Van Den Hout et al., “Surgery versus prolonged conservative treatment for sciatica,” *New England Journal of Medicine*, vol. 356, no. 22, pp. 2245–2256, 2007.

[24] S. J. Atlas, T. D. Tosteson, E. A. Blood, J. S. Skinner, G. S. Pransky, and J. N. Weinstein, “The impact of workers’ compensation on outcomes of surgical and nonoperative therapy for patients with a lumbar disc herniation: SPORT,” *Spine*, vol. 35, no. 1, pp. 89–97, 2010.

[25] D. R. Murphy, E. L. Hurwitz, A. A. Gregory, and R. Clary, “A non-surgical approach to the management of lumbar spinal stenosis: A prospective observational cohort study,” *BMC Musculoskeletal Disorders*, vol. 7, article no. 16, p. 8, 2006.

[26] P. D. D. M. Roelofs, R. A. Deyo, B. W. Koes, R. J. P. M. Scholten, and M. W. Van Tulder, “Nonsteroidal anti-inflammatory drugs for low back pain: An updated cochrane review,” *Spine*, vol. 33, no. 16, pp. 1766–1774, 2008.

[27] T. Gomes, D. N. Juurlink, I. A. Dhallia, A. Mailis-Gagnon, J. M. Paterson, and M. M. Mamdani, “Trends in opioid use and dosing among socio-economically disadvantaged patients,” *Open Medicine*, vol. 5, no. 1, pp. e13–e22, 2011.

[28] A. Minamide, H. Hashizume, M. Yoshida, M. Kawakami, N. Hayashi, and T. Tamaki, “Effects of basic fibroblast growth factor on spontaneous resorption of herniated intervertebral discs: An experimental study in the rabbit,” *Spine*, vol. 24, no. 10, pp. 940–945, 1999.

[29] K. Omaker, B. Rydevik, and C. Nordborg, “Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots,” *Spine*, vol. 18, no. 11, pp. 1425–1432, 1993.

[30] S. D. Gertzbein, M. Tile, A. Gross, and R. Falk, “Autoimmunity in degenerative disc disease of the lumbar spine,” *Orthopedic Clinics of North America*, vol. 6, no. 1, pp. 67–73, 1975.

[31] L. L. Marshall, E. R. Trethewie, and C. C. Curtain, “Chemical radiculitis. A clinical, physiological and immunological study,” *Clinical Orthopaedics and Related Research*, vol. 129, pp. 61–67, 1977.
[32] R. F. McCarron, M. W. Wimpee, P. G. Hudkins, and G. S. Laros, “The inflammatory effect of nucleus pulposus: a possible element in the pathogenesis of low-back pain,” *Spine*, vol. 12, no. 8, pp. 760–764, 1987.

[33] J. D. Kang, H. I. Georgescu, L. McIntyre-Larkin, M. Stefanovic-Racic, W. F. Donaldson, and C. H. Evans, “Herniated lumbar intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2,” *Spine (Phila Pa 1976)*, vol. 21, no. 3, pp. 271–277, 1996.

[34] J. S. Saal, R. C. Franson, R. Dobrow, J. A. Saal, A. H. White, and N. Goldthwaite, “High levels of inflammatory phospholipase A2 activity in lumbar disc herniations,” *Spine (Phila Pa 1976)*, vol. 15, no. 7, pp. 674–678, 1990.

[35] S.-H. Ahn, Y.-W. Cho, M.-W. Ahn, S.-H. Jang, Y.-K. Sohn, and H.-S. Kim, “mRNA expression of cytokines and chemokines in herniated lumbar intervertebral discs,” *Spine*, vol. 27, no. 9, pp. 911–917, 2002.

[36] H. Takahashi, T. Suguro, Y. Okazima, M. Motegi, Y. Okada, and T. Kakiuchi, “Inflammatory cytokines in the herniated disc of the lumbar spine,” *Spine*, vol. 21, no. 2, pp. 218–224, 1996.

[37] P. Goupille, M. I. V. Jayson, J.-P. Valat, and A. J. Freemont, “The role of inflammation in disk herniation-associated radiculopathy,” *Seminars in Arthritis and Rheumatism*, vol. 28, no. 1, pp. 60–71, 1998.

[38] J. Burke, R. Watson, D. McCormack, F. Dowling, M. Walsh, and J. Fitzpatrick, “Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators,” *Bone and Joint Journal*, vol. 84, no. 2, pp. 196–201, 2002.

[39] D. Mulleman, S. Mamhou, I. Griffoul, H. Watier, and P. Goupille, “Pathophysiology of disk-related sciatica. I. Evidence supporting a chemical component,” *Joint Bone Spine*, vol. 73, no. 2, pp. 151–158, 2006.

[40] A. A. Ramelet, “Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency,” *Angiology*, vol. 52, no. 8, pp. S49–S56, 2001.

[41] A.-A. Ramelet, “Pharmacologic aspects of a phlebotropic drug in CVI-associated edema,” *Angiology*, vol. 51, no. 1, pp. 19–23, 2000.